Login
Evidence Feed
About
Conferences
New
Diagnostics
New
Top genes
New
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
HER-2 expression
i
Other names:
ERBB2, CD340, HER-2, HER2, NEU, NGL, V-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
2064
Related biomarkers:
Expression
Mutation
CNA
Fusion
Others
‹
›
Associations
News
Twitter
Trials
Reset Filters
VERI cancer hierarchy
x
x
x
x
HER-2 expression
Gastroesophageal Cancer
HER-2 expression
Gastroesophageal Cancer
ZW25
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks (New C3)
ZW25
Sensitive
:
C3
ASCO-GI 2023 - 2wk
ZW25
Sensitive: C3 – Early Trials
ASCO-GI 2023 - 2 weeks
ZW25
Sensitive
:
C3
ASCO-GI 2023 - 2 weeks - (New C3)
HER-2 expression
Endometrial Adenocarcinoma
HER-2 expression
Endometrial Adenocarcinoma
trastuzumab
Sensitive: A2 - Guideline
trastuzumab
Sensitive
:
A2
trastuzumab
Sensitive: A2 - Guideline
trastuzumab
Sensitive
:
A2
HER-2 expression
Breast Cancer
HER-2 expression
Breast Cancer
ARX788
Sensitive: B - Late Trials
ARX788
Sensitive
:
B
ARX788
Sensitive: B - Late Trials
ARX788
Sensitive
:
B
HER-2 expression
Biliary Tract Cancer
HER-2 expression
Biliary Tract Cancer
ZW25
Sensitive: B - Late Trials
ZW25
Sensitive
:
B
ZW25
Sensitive: B - Late Trials
ZW25
Sensitive
:
B
HER-2 expression
Cholangiocarcinoma
HER-2 expression
Cholangiocarcinoma
trastuzumab + lapatinib
Sensitive: B - Late Trials
trastuzumab + lapatinib
Sensitive
:
B
trastuzumab + lapatinib
Sensitive: B - Late Trials
trastuzumab + lapatinib
Sensitive
:
B
HER-2 expression
HER2 Positive Breast Cancer
HER-2 expression
HER2 Positive Breast Cancer
trastuzumab + pertuzumab
Sensitive: C2 – Inclusion Criteria
trastuzumab + pertuzumab
Sensitive
:
C2
trastuzumab + pertuzumab
Sensitive: C2 – Inclusion Criteria
trastuzumab + pertuzumab
Sensitive
:
C2
HER-2 expression
Gastric Cancer
HER-2 expression
Gastric Cancer
trastuzumab
Sensitive: C2 – Inclusion Criteria
trastuzumab
Sensitive
:
C2
trastuzumab
Sensitive: C2 – Inclusion Criteria
trastuzumab
Sensitive
:
C2
HER-2 expression
HER2 Positive Breast Cancer
HER-2 expression
HER2 Positive Breast Cancer
trastuzumab
Sensitive: C2 – Inclusion Criteria
trastuzumab
Sensitive
:
C2
trastuzumab
Sensitive: C2 – Inclusion Criteria
trastuzumab
Sensitive
:
C2
HER-2 expression
Colorectal Cancer
HER-2 expression
Colorectal Cancer
fam-trastuzumab deruxtecan-nxki
Sensitive: C2 – Inclusion Criteria
fam-trastuzumab deruxtecan-nxki
Sensitive
:
C2
fam-trastuzumab deruxtecan-nxki
Sensitive: C2 – Inclusion Criteria
fam-trastuzumab deruxtecan-nxki
Sensitive
:
C2
HER-2 expression
Gastroesophageal Junction Adenocarcinoma
HER-2 expression
Gastroesophageal Junction Adenocarcinoma
fam-trastuzumab deruxtecan-nxki
Sensitive: C2 – Inclusion Criteria
fam-trastuzumab deruxtecan-nxki
Sensitive
:
C2
fam-trastuzumab deruxtecan-nxki
Sensitive: C2 – Inclusion Criteria
fam-trastuzumab deruxtecan-nxki
Sensitive
:
C2
HER-2 expression
Gastric Cancer
HER-2 expression
Gastric Cancer
A166
Sensitive: C2 – Inclusion Criteria
A166
Sensitive
:
C2
A166
Sensitive: C2 – Inclusion Criteria
A166
Sensitive
:
C2
HER-2 expression
Breast Cancer
HER-2 expression
Breast Cancer
lapatinib
Sensitive: C2 – Inclusion Criteria
lapatinib
Sensitive
:
C2
lapatinib
Sensitive: C2 – Inclusion Criteria
lapatinib
Sensitive
:
C2
HER-2 expression
Colorectal Cancer
HER-2 expression
Colorectal Cancer
A166
Sensitive: C2 – Inclusion Criteria
A166
Sensitive
:
C2
A166
Sensitive: C2 – Inclusion Criteria
A166
Sensitive
:
C2
HER-2 expression
HER2 Positive Breast Cancer
HER-2 expression
HER2 Positive Breast Cancer
A166
Sensitive: C2 – Inclusion Criteria
A166
Sensitive
:
C2
A166
Sensitive: C2 – Inclusion Criteria
A166
Sensitive
:
C2
HER-2 expression
HER2 Positive Breast Cancer
HER-2 expression
HER2 Positive Breast Cancer
avelumab
Sensitive: C2 – Inclusion Criteria
avelumab
Sensitive
:
C2
avelumab
Sensitive: C2 – Inclusion Criteria
avelumab
Sensitive
:
C2
HER-2 expression
Solid Tumor
HER-2 expression
Solid Tumor
fam-trastuzumab deruxtecan-nxki
Sensitive: C2 – Inclusion Criteria
fam-trastuzumab deruxtecan-nxki
Sensitive
:
C2
fam-trastuzumab deruxtecan-nxki
Sensitive: C2 – Inclusion Criteria
fam-trastuzumab deruxtecan-nxki
Sensitive
:
C2
HER-2 expression
Urothelial Cancer
HER-2 expression
Urothelial Cancer
toripalimab + disitamab vedotin
Sensitive: C2 – Inclusion Criteria
toripalimab + disitamab vedotin
Sensitive
:
C2
toripalimab + disitamab vedotin
Sensitive: C2 – Inclusion Criteria
toripalimab + disitamab vedotin
Sensitive
:
C2
HER-2 expression
Solid Tumor
HER-2 expression
Solid Tumor
SBT6050
Sensitive: C2 – Inclusion Criteria
SBT6050
Sensitive
:
C2
SBT6050
Sensitive: C2 – Inclusion Criteria
SBT6050
Sensitive
:
C2
HER-2 expression
Gastric Cancer
HER-2 expression
Gastric Cancer
AST-301
Sensitive: C2 – Inclusion Criteria
AST-301
Sensitive
:
C2
AST-301
Sensitive: C2 – Inclusion Criteria
AST-301
Sensitive
:
C2
HER-2 expression
Gastric Cancer
HER-2 expression
Gastric Cancer
disitamab vedotin
Sensitive: C2 – Inclusion Criteria
disitamab vedotin
Sensitive
:
C2
disitamab vedotin
Sensitive: C2 – Inclusion Criteria
disitamab vedotin
Sensitive
:
C2
HER-2 expression
Gastroesophageal Junction Adenocarcinoma
HER-2 expression
Gastroesophageal Junction Adenocarcinoma
KN026
Sensitive: C2 – Inclusion Criteria
KN026
Sensitive
:
C2
KN026
Sensitive: C2 – Inclusion Criteria
KN026
Sensitive
:
C2
HER-2 expression
Gastric Cancer
HER-2 expression
Gastric Cancer
KN026
Sensitive: C2 – Inclusion Criteria
KN026
Sensitive
:
C2
KN026
Sensitive: C2 – Inclusion Criteria
KN026
Sensitive
:
C2
HER-2 expression
HER2 Positive Breast Cancer
HER-2 expression
HER2 Positive Breast Cancer
ado-trastuzumab emtansine
Sensitive: C3 – Early Trials
ado-trastuzumab emtansine
Sensitive
:
C3
ado-trastuzumab emtansine
Sensitive: C3 – Early Trials
ado-trastuzumab emtansine
Sensitive
:
C3
HER-2 expression
Colorectal Cancer
HER-2 expression
Colorectal Cancer
trastuzumab + tucatinib
Sensitive: C3 – Early Trials
trastuzumab + tucatinib
Sensitive
:
C3
trastuzumab + tucatinib
Sensitive: C3 – Early Trials
trastuzumab + tucatinib
Sensitive
:
C3
HER-2 expression
Salivary Gland Cancer
HER-2 expression
Salivary Gland Cancer
ARX788
Sensitive: C3 – Early Trials
ARX788
Sensitive
:
C3
ARX788
Sensitive: C3 – Early Trials
ARX788
Sensitive
:
C3
HER-2 expression
Colorectal Cancer
HER-2 expression
Colorectal Cancer
ARX788
Sensitive: C3 – Early Trials
ARX788
Sensitive
:
C3
ARX788
Sensitive: C3 – Early Trials
ARX788
Sensitive
:
C3
HER-2 expression
Biliary Tract Cancer
HER-2 expression
Biliary Tract Cancer
ARX788
Sensitive: C3 – Early Trials
ARX788
Sensitive
:
C3
ARX788
Sensitive: C3 – Early Trials
ARX788
Sensitive
:
C3
HER-2 expression
Non Small Cell Lung Cancer
HER-2 expression
Non Small Cell Lung Cancer
ARX788
Sensitive: C3 – Early Trials
ARX788
Sensitive
:
C3
ARX788
Sensitive: C3 – Early Trials
ARX788
Sensitive
:
C3
HER-2 expression
Gastric Cancer
HER-2 expression
Gastric Cancer
ARX788
Sensitive: C3 – Early Trials
ARX788
Sensitive
:
C3
ARX788
Sensitive: C3 – Early Trials
ARX788
Sensitive
:
C3
HER-2 expression
Colorectal Cancer
HER-2 expression
Colorectal Cancer
panitumumab
Resistant: C3 – Early Trials
panitumumab
Resistant
:
C3
panitumumab
Resistant: C3 – Early Trials
panitumumab
Resistant
:
C3
HER-2 expression
HER2 Positive Breast Cancer
HER-2 expression
HER2 Positive Breast Cancer
nivolumab + fam-trastuzumab deruxtecan-nxki
Sensitive: C3 – Early Trials
nivolumab + fam-trastuzumab deruxtecan-nxki
Sensitive
:
C3
nivolumab + fam-trastuzumab deruxtecan-nxki
Sensitive: C3 – Early Trials
nivolumab + fam-trastuzumab deruxtecan-nxki
Sensitive
:
C3
HER-2 expression
Pancreatic Adenocarcinoma
HER-2 expression
Pancreatic Adenocarcinoma
trastuzumab + erlotinib + gemcitabine
Sensitive: C3 – Early Trials
trastuzumab + erlotinib + gemcitabine
Sensitive
:
C3
trastuzumab + erlotinib + gemcitabine
Sensitive: C3 – Early Trials
trastuzumab + erlotinib + gemcitabine
Sensitive
:
C3
HER-2 expression
Colorectal Cancer
HER-2 expression
Colorectal Cancer
trastuzumab + lapatinib
Sensitive: C3 – Early Trials
trastuzumab + lapatinib
Sensitive
:
C3
trastuzumab + lapatinib
Sensitive: C3 – Early Trials
trastuzumab + lapatinib
Sensitive
:
C3
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login